In the second quarter, Cribstone Capital Management LLC acquired Pfizer Inc. (NYSE: PFE – Receive Rating) to 3.0%, the company revealed in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm held 17,035 shares of the biopharmaceutical company’s stock after acquiring an additional 496 shares during the period. At the end of the most recent quarter Cribstone Capital Management LLC’s holding in Pfizer was worth $893,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Pfizer worth approximately $554,000 in the second quarter. Mount Yale Investment Advisors LLC boosted its holding in shares of Pfizer to 3.0% during the second quarter. Mount Yale Investment Advisors LLC now holds 13,298 shares of the biopharmaceutical company valued at $697,000 after buying an additional 383 shares during the period. Advisory Services Network LLC increased its holding in shares of Pfizer to 7.9% during the second quarter. Advisory Services Network LLC now owns 354,858 shares of the biopharmaceutical company valued at $18,606,000 after buying an additional 25,871 shares during the period. Journey Advisory Group LLC increased its holding in shares of Pfizer to 31.6% during the second quarter. Journey Advisory Group LLC now holds 91,702 shares of the biopharmaceutical company valued at $4,642,000 after purchasing an additional 22,011 shares during the period. Finally, JFS Wealth Advisors LLC boosted its holding in shares of Pfizer to 1.1% during the second quarter. JFS Wealth Advisors LLC now holds 47,816 shares of the biopharmaceutical company valued at $2,507,000 after buying additional 508 shares during the period. Institutional investors hold 67.90% of the company’s shares.
Wall Street analysts forecast growth
Several brokerages have recently commented on PFE. Barclays raised its target price on shares of Pfizer from $44.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2. SVB Leerink raised its target price on shares of Pfizer from $48.00 to $49.00 and gave the stock a “market perform” rating in a report on Thursday, November 3. Berenberg Bank set $44.00 price objective on shares of Pfizer in a report on Wednesday, September 14. Credit Suisse Group initiated coverage on shares of Pfizer in a report on Thursday. He issued an “Outperform” rating and $55.00 price objective for the company. Finally, StockNews.com began coverage on shares of Pfizer in a report on Wednesday, October 12. He issued a “strong-buy” rating for the company. Nine investment analysts have a hold rating on the company’s stock, seven have a buy rating and one has a strong buy rating on the company’s stock. The company has an average rating of “medium buy” and a consensus price target of $56.56, according to Marketbeat.
pfizer price performance
Shares of NYSE:PFE opened on Friday at $48.23. The firm’s 50-day moving average is $45.36 and 200-day moving average is $48.51. The stock has a market capitalization of $270.73 billion, a PE ratio of 9.28, a PEG ratio of 0.60, and a beta of 0.69. The company has a current ratio of 1.59, quick ratio of 1.37 and debt-to-equity ratio of 0.35. Pfizer Inc. The 12-month low is $41.44 and the 12-month high is $61.71.
pfizer dividend announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. A dividend of $0.40 per share will be paid to investors of record on Friday, November 4th. This represents a $1.60 dividend and a yield of 3.32% on an annualized basis. The ex-dividend date is Thursday, November 3. Pfizer’s dividend payout ratio is 30.77%.
Pfizer Inc. discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers drugs and vaccines under the Premarin family and Eliquis brands in various therapeutic areas including cardiovascular metabolism and women’s health; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Extandi, Sutent, Inalita, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective drugs, and oral COVID-19 treatments under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see which other hedge funds are holding PFE? Pfizer Inc. (NYSE:PFE – Get Ratings) Visit HoldingsChannel.com to get the latest 13F filings and insider trades.
Receive news and ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.